These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22295149)

  • 1. Primary central nervous system B cell lymphoma with features intermediate between diffuse large B cell lymphoma and Burkitt lymphoma.
    Jiang L; Li Z; Finn LE; Personnet DA; Edenfield B; Foran JM; Jaeckle KA; Reimer R; Menke DM; Ketterling RP; Tun HW
    Int J Clin Exp Pathol; 2012; 5(1):72-6. PubMed ID: 22295149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
    Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
    Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.
    Xu T; Jia Q; Wang Y; Liu Y; Han D; Li P; Ma J; Fan L; Yan Q; Guo S; Li M; Wang Z
    Diagn Pathol; 2019 May; 14(1):45. PubMed ID: 31109360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
    Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
    Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
    [No Abstract]   [Full Text] [Related]  

  • 5. MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.
    Nosrati A; Monabati A; Sadeghipour A; Radmanesh F; Safaei A; Movahedinia S
    Ann Hematol; 2019 Jan; 98(1):169-173. PubMed ID: 30306208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A highly therapy-resistant case of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma showing strong BCL2 staining, otherwise indistinguishable from Burkitt lymphoma.
    Kurita N; Nishikii H; Nakamoto R; Nakamura N; Kondo Y; Okoshi Y; Suzukawa K; Hasegawa Y; Yokoyama Y; Noguchi M; Chiba S
    J Clin Exp Hematop; 2011; 51(1):37-42. PubMed ID: 21628859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
    Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
    Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.
    Pillai RK; Sathanoori M; Van Oss SB; Swerdlow SH
    Am J Surg Pathol; 2013 Mar; 37(3):323-32. PubMed ID: 23348205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double-hit high-grade B-cell lymphoma, and single-hit MYC-rearranged diffuse large B-cell lymphoma.
    Tsagarakis NJ; Papadhimitriou SI; Pavlidis D; Liapis K; Gortzolidis G; Kostopoulos IV; Marinakis T; Paterakis G
    Cytometry B Clin Cytom; 2020 Sep; 98(5):412-420. PubMed ID: 32497402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central nervous system infiltration of a multiple cytokine-producing double-hit B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma with CC chemokine receptor 7 expression.
    Nakayama S; Yokote T; Iwaki K; Hiraoka N; Hirata Y; Akioka T; Miyoshi T; Takayama A; Nishiwaki U; Masuda Y; Tsuji M; Hanafusa T
    Acta Oncol; 2013 Aug; 52(6):1217-20. PubMed ID: 23205745
    [No Abstract]   [Full Text] [Related]  

  • 11. Aggressive B cell lymphomas of the gastrointestinal tract: clinicopathologic and genetic analysis.
    Choi SY; Kim SJ; Kim WS; Kim K; Ko YH
    Virchows Arch; 2011 Nov; 459(5):495-502. PubMed ID: 22002677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.
    Wang W; Hu S; Lu X; Young KH; Medeiros LJ
    Am J Surg Pathol; 2015 Aug; 39(8):1132-9. PubMed ID: 25828391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
    Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
    Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
    Landsburg DJ; Petrich AM; Abramson JS; Sohani AR; Press O; Cassaday R; Chavez JC; Song K; Zelenetz AD; Gandhi M; Shah N; Fenske TS; Jaso J; Medeiros LJ; Yang DT; Nabhan C
    Cancer; 2016 Feb; 122(4):559-64. PubMed ID: 26565895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Doublehit lymphomas -  review of the literature and case report].
    Smardová J; Moulis M; Lišková K; Koptíková J; Hrabálková R; Klusáková J
    Klin Onkol; 2014; 27(1):24-32. PubMed ID: 24635434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary central nervous system lymphomas associated with chronic inflammation: diagnostic pitfalls of central nervous system lymphomas.
    Sugita Y; Masuoka J; Kameda K; Takahashi K; Kimura Y; Higaki K; Furuta T; Ohshima K
    Brain Tumor Pathol; 2020 Oct; 37(4):127-135. PubMed ID: 32627089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological features of double-hit B-cell lymphomas with MYC and BCL2, BCL6 or CCND1 rearrangements.
    Yoshida M; Ichikawa A; Miyoshi H; Kiyasu J; Kimura Y; Arakawa F; Niino D; Ohshima K
    Pathol Int; 2015 Oct; 65(10):519-27. PubMed ID: 26224092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of the GMALL-B-ALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non-Hodgkin-lymphomas with or without CNS involvement.
    Sakarou M; Eisele L; Dührsen U; Hüttmann A
    Eur J Haematol; 2019 Mar; 102(3):241-250. PubMed ID: 30471148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Burkitt lymphoma (BL): reclassification of 39 lymphomas diagnosed as BL or Burkitt-like lymphoma in the past based on immunohistochemistry and fluorescence in situ hybridization.
    Kodet R; Mrhalová M; Stejskalová E; Kabícková E
    Cesk Patol; 2011 Jul; 47(3):106-14. PubMed ID: 21887927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large B-cell lymphoma.
    Zajdel M; Rymkiewicz G; Chechlinska M; Blachnio K; Pienkowska-Grela B; Grygalewicz B; Goryca K; Cieslikowska M; Bystydzienski Z; Swoboda P; Walewski J; Siwicki JK
    Tumour Biol; 2015 Jul; 36(7):5377-88. PubMed ID: 25677902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.